Evaluation of AryoTrust administration in treatment of breast cancer

Phase 4

Recruiting

• Conditions: Breast cancer.; Malignant neoplasm of unspecified site of unspecified female breast; C50.919

• Registration Number: IRCT20150303021315N16
• Lead Sponsor: Aryogen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 December 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 597

Inclusion Criteria

Patients diagnosed with non-metastatic HER2 positive breast cancer after treatment with adjuvant chemotherapy (trastuzumab in combination with doxetaxel or paclitaxel weekly for 12 weeks or others regimens) who are candidates for trastuzumab maintenance therapy 6 mg/kg every 3 weeks for 12 months

Exclusion Criteria

-Patients who received Herceptin
-Patients who are not candidates for trastuzumab maintenance therapy after adjuvant chemotherapy

Study & Design

• Study Type: observational
• Study Design: Not specified